27:12 Marknadsuppdatering om Novo Nordisk, Egetis Therapeutics, Hansa Biopharma och Sobi
26.04.2023 Q1 Kvartalsrapport
27.04.2023 Generalforsamling
Og så er det mulig, muligens ikke, en presentasjon hos Redeye i morgen.
Satser på noen drypp morgen 
1 Like
Interim report January-March 2023
April 26, 2023
Gjentar:
· In light of existing rumors in the market the Board of Directors of Egetis made the following statement: Egetis has ongoing discussions with certain external parties regarding a potential acquisition of the company. There can be no certainty that a public take-over offer will be made, nor as to the terms of any such offer
Ingen Q1-webcast i dag
Hele rapporten https://www.egetis.com/mfn_news/interim-report-january-march-2023/
1 Like
NDA pushet fra mid 2023 til 2H og nå Q4’23. EMA on track.
The Emcitate project is progressing with focus on applications for market approvals in the US and EU in 2023
We work intensively to submit a marketing authorization application for Emcitate to the EMA in the second quarter of 2023, based on existing clinical data, after sufficient stability data has been obtained for the commercial product of Emcitate .
As previously communicated, Egetis will conduct a confirmatory randomized placebo-controlled trial in 16 patients to verify the results of previous clinical trials and publications regarding thyroid hormone T3 levels.
Based on regulatory feedback on the documentation for the ReTRIACt study, certain clinical trial documentation has been updated, which necessitates renewed approvals from the ethics committees at the three participating hospitals, and if necessary, regulatory authorities. This work has started and is expected to result in the first patient being treated in the second quarter. In parallel, we have commenced the work to identify possible study participants, and so far we have identified >30 patients at the various trial sites. Therefore, our overall assessment is that this administrative delay of the start of the study will not significantly affect the timing of the submission of a marketing application in the USA. Egetis plans to submit an NDA in the USA in the fourth quarter of 2023 under the ’Fast Track Designation’ granted by the FDA. The design of the study is available on clinicaltrials.gov under the code NCT05579327.
Ingen ny info som håpet, men de bekrefter at prosessen pågår.
Worst case faller transaksjonen i grus og Egetis må kjøre en emisjon i andre halvår og ta launch på egenhånd 
1 Like
PAS: Q1 takes – Risk of further delays looming
This morning, Egetis Therapeutics released their Q1 report with material updates. The number of patients on Emcitate increased from over 170 to around 180 the last quarter, confirming the need for Emcitate in this ultra-rare disease. The small 16 patients’ trial required for FDA approval has suffered from an ongoing delay. The company now expects the first patient to be treated in Q2. However, considering the long existing delay with very little information on its nature and the statement by the company that the FDA might need to approve new changes to the trial, we see a heightened execution risk for the trial. Regarding Europe, the EMA submission is planned for Q2, where the final stability data of Emcitate should be available. Egetis reported a cash balance of SEK 243m with an increased quarterly burn rate of SEK -75m, which should last the company into Q4 2023. We have a Buy rating on EGTX with a target price of SEK 24.
1 Like
Lignende melding og ordlyd fra oppkjøp av Horizon Therapeutics. To uker fra melding om «highly preliminary discussions» til cash offer.
Nov. 29, 2022-- The Board of Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon” or the “Company”) confirms that it is engaged in highly preliminary discussions with Amgen Inc., Janssen Global Services, LLC and Sanofi (each a " Possible Offeror ") which may or may not lead to an offer being made for the entire share capital of the Company. There can be no certainty that any offer will be made for the Company.
Dec.12, 2022–The board of directors of Horizon Therapeutics plc(the “ Company ” or “ Horizon ”) and the board of directors of Amgen Inc. (“ Amgen ”) are pleased to announce that they have reached agreement on the terms of a cash offer for the Company by Pillartree Limited (“ Acquirer Sub ”), a newly formed private limited company wholly owned by Amgen
1 Like
Kursen stiger på anaylseoppdateringen under. Bull sammenligning med oppkjøp av Wilson!
I tillegg har selskapet fått godkjent nytt styremedlem på generalforsamlingen i går. Man får håpe på hektisk møteaktivitet i helgen
Merger Monday is a term invented by Wall Street to denote the fact that major players in the market often finalize major mergers and acquisitions during the weekend and announce them on Monday.
Penser Access
I väntan på studiestart - Egetis Therapeutics
Lite tankar kring potentiellt uppköp och motiverat värde
Angående de budrykten som figurerat i marknaden så upprepar bolaget i rapporten det budskap som skickats ut tidigare. Den mest relevanta referensen för ett potentiellt bud är som vi ser det Alexions uppköp av Wilson Therapeutics som gjordes för 6,5 miljarder kronor under 2018. Wilsons huvudkandidat, WTX101, var vid tiden för uppköpet dock något längre ifrån marknad än vad Emcitate är nu. Vi anser att Wilson-transaktionen kan utgöra en rimlig indikation på vad storägarna i Egetis kan vara beredda att acceptera i termer av bud. En affär i denna storlek skulle motsvara 26 kronor per aktie med nuvarande aktiestock i Egetis.
Vårt motiverade värde om 11–12 kronor är baserat på ett aktiemarknadsperspektiv och det höga avkastningskrav investerare i sektorn för tillfället har på svenska forskningsbolag. En större industriell spelare som är intresserad av att köpa Egetis har sannolikt ett väsentligt lägre avkastningskrav, därav bedömer vi att ett bud kan överstiga vårt nuvarande motiverade värde kraftigt.
Läs den fullständiga analysen, publicerad 28-04-2023 kl. 08:13: https://docs.penser.se/a/3667/EGETIS20230428.pdf
1 Like
Oppdatert selskapspresentasjon https://www.egetis.com/wp-content/uploads/Egetis-Corporate-Presentation-May-2023.pdf
Spennende år foran - også å se om selskapet forblir selvstendig så lenge
1 Like
the Board believes the contemplated offer and terms, while providing a premium to the current share price, considerably undervalued the long-term prospects of the Company.
1 Like
Redye
Redeye has a neutral take on the announcement that the discussions of a potential acquisition of Egetis have been terminated, as the offer and terms “while providing a premium to the current share price, considerably undervalued the long-term prospects of the Company”. We argue that Egetis has been significantly undervalued for some time now and would have wanted to see a significant premium to be positive to an acquisition, further supported by Egetis short remaining time to market with Emcitate and also given that the company and previous owners have the right to a priority review voucher worth in total USD100m, that can be sold, after the US approval. In the same release, we learn that the timeline for the submission of the marketing authorization application (MAA) in the EU for Emcitate has been pushed from Q2 to early autumn (ie likely September of October). It has no immediate impact on valuation, although it could somewhat impact the stock sentiment in the near term as we wait for further progress.
… Salgbar voucher etter FDA godkjenning. Klarer de lande noe slikt…?